Celator Pharmaceuticals Inc. (Nasdaq: CPXX) reported positive results from a Phase 3 trial of VYXEOS to treat patients with high risk acute myeloid leukemia. Shares of the biopharmaceutical more than tripled by leaping $5.82 to $7.50.
Celator Pharmaceuticals reports upbeat study resultsMarch 15, 2016 at 12:56 PM EDT
Celator Pharmaceuticals Inc. (Nasdaq: CPXX) reported positive results from a Phase 3 trial of VYXEOS to treat patients with high risk acute myeloid leukemia. Shares of the biopharmaceutical more than tripled by leaping $5.82 to $7.50.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|